PolyPid partners with Azurity to commercialize D-PLEX100 in US, Canada

PolyPid

PolyPid

PYPD

0.00
  • PolyPid entered an exclusive deal with Azurity to commercialize D-PLEX100 in the US, Canada for surgical site infection prevention.
  • Upfront payment set at USD 15 million on signing; USD 15 million milestone due on FDA NDA acceptance expected in August 2026.
  • Eligible for about USD 300 million in additional regulatory, development, sales milestones; tiered royalties in the mid-teens to mid-twenties.
  • PolyPid to manufacture and supply D-PLEX100; Azurity to fund clinical development, including potential US, Canada label expansion beyond abdominal surgery.
  • US launch targeted for Q1 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PolyPid Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607210730PRIMZONEFULLFEED9764424) on July 21, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.